A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors.

Trial Profile

A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2009 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
    • 12 Apr 2007 Status changed from initiated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top